T he 26S proteasome is a large adenosine triphosphate (ATP)-dependent multimeric complex that degrades intracellular proteins targeted for proteolysis by the process of ubiquitination. [1] [2] [3] [4] Protein ubiquitination followed by proteasome-mediated degradation is a major pathway for protein turnover, but it also plays an important role in intracellular signaling through modulation of the levels of intracellular signaling mediators, such as the inhibitor of nuclear factor-B (NF-B) IB, 5 p53, 6 -8 and c-Jun N-terminal kinase (JNK). 9 Proteasome inhibitors constitute a novel class of antitumor agents with preclinical evidence of activity against hematologic malignancies and solid tumors. 10, 11 Specifically, bortezomib, a boronic acid dipeptide with selective activity as a proteasome inhibitor, has demonstrated clinical efficacy in patients with multiple myeloma 12 and is approved by the US Food and Drug Administration (FDA) for that indication. 13 It is under evaluation for its activity in a variety of other hematologic and solid malignancies. 14 -18 An important effect of proteasome inhibition on cell biology is the abrogation of proteasomal degradation of the NF-B inhibitor IB. Proteasome inhibitors induce cytoplasmic accumulation of IB, which then blocks the nuclear translocation and transcriptional activity of NF-B. Other NF-B-independent effects of bortezomib on myeloma cells include the stabilization of p53 protein and the upregulation of p53 mRNA, the stabilization of c-myc, 19 and the phosphorylation and activation of c-Jun. 19 These effects may contribute to the proapoptotic impact of bortezomib in various different types of cancer cells in vitro and, possibly, in vivo. 19, 20 It appears that cancer cells are more sensitive than healthy cells to proteasome inhibition, possibly because of their chaotic cell cycles and their genetic instability. Moreover, bortezomib sensitizes malignant cells to cytotoxic chemotherapeutic agents by downregulation of the NF-B-dependent expression of several inhibitors of apoptosis such as A1, cellular inhibitor of apoptosis protein-2 (cIAP2), and X-linked inhibitor of apoptosis protein (XIAP). 21 Retinoblastoma is the most common intraocular malignancy of childhood. Human retinoblastoma cells exhibit constitutive transcriptional activity of NF-B, which is necessary for their survival. 22 Therefore, therapeutic strategies targeting NF-B could be beneficial in the clinical management of retinoblastoma. In this study, we evaluated the in vitro effect of bortezomib on the retinoblastoma cells lines WERI-Rb1 and Y79. We found that both retinoblastoma cell lines were sensitive to bortezomib and underwent caspase-dependent apoptosis. These studies therefore provide the framework for the use of proteasome inhibitor-based therapies in the treatment of aggressive retinoblastomas.
Total RNA was extracted and purified with the RNeasy kit (Qiagen, San Diego, CA). Five micrograms of total RNA was used in the first-strand cDNA synthesis with T7-d(T) 24 primer (GGCCAGTGAATTGTAATAC-GACTCACTATAGGGAGGCGG-(dT) 24 ) and Superscript II (Invitrogen). Second-strand cDNA synthesis was carried out at 16°C by adding Escherichia coli DNA ligase, E. coli DNA polymerase I, and RNase H to the reaction, followed by T4 DNA polymerase to blunt the ends of newly synthesized cDNA. cDNA was purified through phenol/chloroform and ethanol precipitation. The purified cDNA was incubated at 37°C for 5 hours in an in vitro transcription reaction to produce cRNA labeled with biotin (BioArray High Yield RNA Transcript Labeling Kit; Enzo Diagnostics, Farmingdale, NY).
Affymetrix Chip Hybridization
cRNA (20 g ) was fragmented by incubation in buffer containing 200 mM Tris-acetate (pH 8.1), 500 mM KOAc, and 150 mM MgOAc at 94°C for 35 minutes. The hybridization cocktail containing 15 g adjusted fragmented cRNA mixed with eukaryotic hybridization controls (control cRNA and oligonucleotide B2) was hybridized with a pre-equilibrated human chip (U133 2.0 Plus; Affymetrix Inc., Santa Clara, CA) at 45°C for 16 hours. After the hybridization cocktails were removed, the chips were washed in a fluidic station with low-stringency buffer (6ϫ standard saline phosphate with EDTA, 0.01% Tween 20, and 0.005% antifoam) for 10 cycles (2 mixes/cyc) and high-stringency buffer (100 mM N-morpholino-ethanesulfonic acid [MES]), 0.1 M NaCl, and 0.01% Tween 20) for four cycles (15 mixes/cyc) and stained with streptavidin phycoerythrin. This process was followed by incubation with normal goat IgG and biotinylated mouse anti-streptavidin antibody and restaining with streptavidin phycoerythrin. The chips were scanned (HP ChipScanner; Affymetrix Inc.) to detect hybridization signals.
Data Analysis
Scanned image output files were visually examined for major chip defects and hybridization artifacts and then were analyzed with microarray analysis software (GeneChip Microarray Analysis Suite 5.0; Affymetrix). The image from each gene chip was scaled such that the average intensity value for all arrays was adjusted to a target intensity of 150. Expression analysis files created by the software were exported as flat text files to a spreadsheet (Excel; Microsoft, Redmond, WA) for further analysis. Data analysis identified signals with at least a twofold difference between bortezomib-treated samples and respective controls. These results were screened for P Ͻ 0.0025, Student's t-test, to identify induced or repressed transcripts. Information and annotations for all genes were retrieved using the NetAffx website (www. affymetrix.com/analysis/index.affx) and UnChip (unchip.org:8080/ bio/unchip; Alberto Riva, Atul Butte, and Isaac Kohane; Children's Hospital, Boston), as previously reported, 19 and were added to the data file. Annotated data were sorted according to functional relationships.
Validation of Expression Array Results by RT-PCR
Confirmation of the microarray results was performed for selected genes, chosen based on putative function, by RT-PCR. Primers for 80-to 130-bp PCR targets were designed with primer analysis software (Oligo 6.69; Molecular Biology Insights, Cascade, CO; Table 1 ). Y79 cells treated with bortezomib for 0, 2, 4, 8, 16, and 24 hours were harvested, and RNA was extracted with reagent (TRIzol-LS; Invitrogen), according to manufacturer's instructions. RNA was further cleaned with an additional DNAse I digestion step using a commercial kit (RNeasy Micro kit; Qiagen), according to manufacturer's instructions. Reverse transcription was performed for equal RNA amounts (1 g, as measured by UV spectrophotometry) with random hexamers and reagent (Superscript II; Invitrogen) with a final step of RNase H digestion (all reagents from Invitrogen). PCR amplification of the resultant cDNAs was performed with PCR beads (Ready-to-Go; Amersham), with final concentrations of 2 mM for MgCl 2 and 150 to 200 nM each primer, for 45 cycles at annealing temperatures, depending on each primer set (60°C-68°C). The housekeeping gene was hypoxanthine guanine phosphoribosyltransferase 1 (HPRT1). Protocols were standardized for optimal annealing temperatures, amplification thresholds, and specificity of melting curves with SYBR Green I in a DNA engine (Opticon; MJ Research, Waltham, MA) with the version 2.01 software (Opticon; MJ Research). PCR products were visualized by electrophoresis on 2% agarose gels.
Statistical Analysis
To evaluate the differences across various experimental conditions in the viability experiments with bortezomib, one-way analysis of variance was performed, and post hoc tests (Duncan and Dunnett T3 tests) were used to evaluate differences between individual pairs of experimental conditions. IC 50 was calculated with the help of statistical analysis software (Statistica; StatSoft, Tulsa, OK). In all analyses, P Ͻ 0.05 was considered statistically significant.
RESULTS

Effect of the Proteasome Inhibitor Bortezomib on Survival of Retinoblastoma Cells
We treated the retinoblastoma cell lines Y79 and WERI-Rb1 in vitro with bortezomib (0 -100 nM) for 24 hours and evaluated their viability using the MTT assay. These cell lines were sensitive to bortezomib-induced cell death and had IC 50 values of 10 and 4.4 nM, respectively (calculated by MTT; Fig. 1A ). Concentrations were well within those achieved clinically in patients treated with bortezomib. 18 Bortezomib-treated cells exhibited a prominent sub-G 1 peak on propidium iodide analysis, indicating induction of apoptosis (Figs. 1B, 1C ).
Effect of Bortezomib on the NF-B Inhibitor IB
We next investigated the effect of proteasome inhibition on cellular levels of the NF-B inhibitor IB levels in retinoblastoma cells. We found that bortezomib treatment resulted in the accumulation of phosphorylated and total IB levels (Fig. 2) .
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Transcriptional Profile of Bortezomib-Treated Retinoblastoma Cells
To define molecular pathways regulating proteasome inhibitorinduced apoptosis, we characterized the gene expression profiles of Y79 and WERI-Rb1 cells treated with bortezomib (25 nM for 2-24 hours) and compared the profiles with those of vehicle-treated controls harvested at the same time point using the human gene chip (U133 2.0 Plus; Affymetrix). Analyses of these gene expression profiles showed that bortezomib induced distinct patterns of coordinated changes in a range of transcripts, including the downregulation of growth and antiapoptotic transcripts, the induction of members of proapoptotic and stress cascades, the upregulation of components of the proteasome/ubiquitin pathway, and an especially potent upregulation of heat-shock protein (HSP) transcripts. Lists of known genes whose transcripts demonstrated the most prominent changes on treatment with bortezomib are presented in Tables 2 and 3 . For validation, selected transcripts were studied by RT-PCR (Fig. 3) .
Effect of Bortezomib Treatment on p53, p21, and p27 Expression
We investigated further the mechanism of bortezomib-induced apoptosis. Subsequent experiments were performed in both retinoblastoma cell lines and yielded similar results (representative results are shown). We evaluated the protein levels of p53, a proteasome substrate, 6 -8 p21, and p27 in bortezomib-treated retinoblastoma cells. We found that bortezomib potently increased the protein levels of p53, p21, and p27 (Fig. 4) . This pathway may contribute to the antigrowth and proapoptotic effects of bortezomib on retinoblastoma cells.
Effect of Bortezomib Treatment on c-Jun Phosphorylation
Treatment with bortezomib resulted in the upregulation of c-Jun mRNA (Tables 2 and 3 ), c-Jun protein, and phospho-c-Jun (Fig. 4 ) levels.
Role of Caspases in Bortezomib-Induced Apoptosis in Retinoblastoma Cells
We then investigated the role of caspases in bortezomib-induced apoptosis of retinoblastoma cells. Bortezomib induced the cleavage of caspases during apoptosis in retinoblastoma cells (Fig. 5A) . Cleavage of the caspase substrate PARP was also detected on bortezomib-treated cells, confirming the enzymatic activation of caspases (Fig. 5A) . Pretreatment of retinoblastoma cells with the pan-caspase inhibitor ZVAD-FMK (20 M) starting 1 hour before treatment with bortezomib had a strong attenuating effect on bortezomib-induced apoptosis (Figs. 5B-D) . Overall, our data support a role for the caspase cascade as a mediator of bortezomib-induced apoptosis in retinoblastoma cells.
Involvement of Bcl-2 Family Members in Bortezomib-Induced Apoptosis of Retinoblastoma Cells
We then studied the expression of several members of the Bcl-2 family of apoptosis modulators. We detected the cleavage of Bid, which is a proapoptotic member of the family, and the upregulation of Noxa and PUMA, in agreement with our microarray data (Fig. 6A) . These data suggest an implication of Bcl-2 family members in bortezomib-induced apoptosis of retinoblastoma cells. 
Effect of Bortezomib Treatment on Heat Shock Protein Expression
Treatment of retinoblastoma cells with bortezomib resulted in the potent upregulation of HSP70 mRNA (as shown earlier) and protein ( Fig. 6B ) and the less prominent upregulation of HSP90.
Effect of Bortezomib Treatment on DoxorubicinInduced Apoptosis in Retinoblastoma Cells
We studied the effect of bortezomib on the response of retinoblastoma cells to the chemotherapeutic drug doxorubicin, which is frequently used for the treatment of retinoblastoma. We found that bortezomib enhanced the proapoptotic effect of doxorubicin (Fig. 7) .
DISCUSSION
In the present study, we investigated the impact of the proteasome inhibitor bortezomib on retinoblastoma cell lines and found that it induces caspase-dependent apoptosis at concentrations well below the trough levels of bortezomib observed in pharmacokinetic studies in humans 18 and significantly lower than those necessary to kill cells from solid tumors (colon, ovary, prostate). These findings support the use of proteasome inhibitor-based therapies in the treatment of aggressive retinoblastomas.
Proteasome inhibitors represent a novel class of antineoplastic agents that target several signaling pathways simultaneously: they block the degradation and lead to the accumulation of IB, 5 which prevents the activation of transcription factor NF-B 5, 19 ; they stabilize the proapoptotic p53 protein 6 -8 ; and they induce the activation of the JNK/jun pathway, 19 reactive oxygen species (ROS) production and resultant mitochondrial injury, 24 and the caspase pathway. 19 Bortezomib, a potent proteasome inhibitor that shows no significant inhibitory activity against other enzymatic systems, has demonstrated clinical activity in patients with relapsed refractory multiple myeloma 12 and has been approved by US FDA for this indication.
13 Phase 1 studies in pediatric patients with refractory solid tumors and hematologic malignancies have demonstrated that bortezomib is well tolerated in children. The recommended phase 2 dose of bortezomib for children with solid tumors is 1.2 mg/m 2 per dose, and for children with leukemia it is 1.3 mg/m 2 per dose, administered as an intravenous bolus twice weekly for 2 weeks followed by a 1-week break. 25, 26 As do multiple myeloma cells, retinoblastoma cells exhibit high baseline NF-B activity, which is necessary for their survival. 22 In the present study, bortezomib-induced inhibition of IB degradation by the proteasome resulted in IB accumulation, which would bind NF-B and sequester it in the cytoplasm, preventing its translocation to the nucleus and sensitizing the cell to apoptosis. The proteasome inhibitor MG132 has also been shown to stabilize p53 and IB and to act synergistically with sodium butyrate in inducing apoptosis of Y79 cells. 27 To better characterize the effects of bortezomib on retinoblastoma cells and to delineate its signaling pathways, we studied the expression profile of bortezomib-treated retinoblastoma cells using microarray analysis. We found that bortezomib treatment results in a specific coordinated pattern of transcriptional events consistent with its proapoptotic effects-the downregulation of transcripts involved in key growth/survival signaling pathways and the upregulation of transcripts implicated in proapoptotic and stress pathways. Other gene families that were modulated were those of the HSP-ubiquitin-proteasome pathway and solute carrier/transport proteins. This transcriptional profile of the bortezomib-treated retinoblastoma cells was remarkably similar between the two retinoblastoma More specifically, we found that bortezomib targets transcripts with prominent roles in cell growth and apoptosis signaling. Specifically, bortezomib upregulated the proapoptotic Bcl-2 family members Noxa (also known as PMA-induced protein 1 [PMAIP1] and implicated in mediating apoptosis induced by cellular stress, DNA damage, and p53 activation, resulting in the activation of caspase-9 28 ), PUMA, and harakiri and serine/threonine protein kinase 17A (STK17A, also known as DAP kinase-related apoptosis-inducing protein kinase 1), which induces apoptosis. 29, 30 Moreover, bortezomib suppressed the transcript for the inhibitor of apoptosis survivin. This transcriptional profile could contribute to the induction of apoptosis by bortezomib. Furthermore, bortezomib potently triggered the transcription of genes related to ubiquitin-proteasome function (such as several proteasome subunits) and molecular chaperones of the HSP family (HSP70, HSP27, HSP40, HSP47) . It is possible that these changes represent a stress response because bortezomibtreated tumor cells unsuccessfully attempt to compensate for the loss of proteasome activity by synthesizing new proteasomes (to restore proteasome activity) and new chaperones (to keep proteins in the correct conformation and lessen the need for proteasomal degradation). HSPs are induced in response to various stress stimuli, such as heat shock, oxidative free radicals, metal ions, and toxins. The human HSP70 or HSPA multigene family comprises several highly conserved 70-kDa proteins required for cancer cell growth and survival. 31 The HSP70 -1 (HSPA1A) and HSP70 -2 (HSPA1B) coding sequences differ by 8 bp that do not alter the derived amino acid sequence and are not interrupted by introns.
32 HSP70 binds to the 3-prime untranslated region of mRNAs for cytokines and protooncogenes and protects them from degradation, thus exerting an antiapoptotic function. 33 Another transcript upregulated by bortezomib was the transcript for Bcl-2-associated athanogene (BAG)-3, a stress-inducible protein that interacts with the heat shock proteins 70, regulates chaperone protein activities, and promotes cell survival by enhancing the antiapoptotic effect of Bcl-2. 34 We detected increased Jun and Fos mRNA and increased total and phospho-Jun protein levels in bortezomib-treated retinoblastoma cells, suggesting an involvement of the JNK (stress-activated protein kinase [SAPK])/AP-1 pathway in the stress response to NF-B inhibition. Also found to be induced by bortezomib in our study were other stress pathway mediators, such as growth arrest-and DNA damage-inducible gene alpha (GADD45A, a stress-induced nuclear protein involved in growth arrest and DNA repair 35 ) and DNA damage-inducible transcript 3, also known as growth arrest-and DNA damage- inducible gene (GADD153), a member of the CAAT/enhancer binding protein (C/EBP) family of transcription factors capable of triggering growth arrest and apoptosis. 36 The latter is known to be induced by AP-1, 37 hypoxia, 38 proteasome inhibition, 39 and endoplasmic reticulum (ER) stress. 40 Because ER is the site of synthesis and folding of secretory proteins, ER dysfunction affects protein folding, leading to high load of misshapen proteins that must be degraded through the ubiquitin-proteasome pathway. Conversely, the inhibition of proteasome activity results in ER stress. When ER function is severely impaired, GADD153 plays a key role in triggering apoptosis, 40 together with the JNK/Jun pathway and caspase-12, 41 which were also found to be activated by bortezomib in our study. In addition, two other members of the C/EBP family, C/EBP␤ and C/EBP␥, were induced by bortezomib in our study.
Another transcription factor modulated by bortezomib in our model was activating transcription factor 3 (ATF3), a member of the mammalian activation transcription factor/cAMP responsive element-binding (CREB) protein family of transcription factors and an immediate early response gene induced in cells exposed to a variety of stress stimuli, including ER stress 42 and proteasome inhibition. 39, 43 ATF3 frequently functions as a complex with GADD153. 42 ATF3 plays a critical role in accelerating caspase activation and apoptosis in response to chemotherapeutic and noxious agents. 44 -47 ATF3 induces another stress response gene, growth arrest and DNA damage inducible gene GADD34 (also known as protein phosphatase 1 regulatory [inhibitor] subunit 15A (PPP1R15A)), 48 which was also upregulated by bortezomib in our study.
Finally, other prominent bortezomib-induced expression pattern changes involved extracellular matrix and adhesion molecules, solute carriers, and transport proteins. Bortezomib increased p53, p21, and p27 protein levels in retinoblastoma cells. p53 is an additional proteasome substrate, and proteasome inhibition stabilizes p53 protein levels. 7, 8 The p21 gene is a transcriptional target of p53, and the p21 protein is also degraded by the proteasome, 49 thus suggesting two possible mechanisms for the upregulation of p21 protein levels (transcriptional and posttranslational). These findings may support a p53/p21-mediated signaling pathway for growth arrest and apoptosis induced by proteasome inhibitors. 7 It should be pointed out, however, that proteasome inhibitors are effective in inducing apoptosis even in tumor cells that lack functional p53.
Bortezomib induced caspase-dependent apoptosis in retinoblastoma cells. Cleavage of caspases-9, -3, and -12 was found (retinoblastoma cells do not express caspase-8 because of epigenetic gene silencing by overmethylation 50 ), and caspase inhibition protected retinoblastoma cells from bortezomib-induced apoptosis, thus confirming the role of the caspase cascade in our model. Finally, bortezomib sensitized retinoblastoma cells to sublethal concentrations of conventional DNA-damaging chemotherapeutic agents, such as doxorubicin, in agreement with similar results in other malignancies. 20, 21 A synergistic interaction has also been reported for the combination of the chemotherapeutic agent camptothecin with the proteasome inhibitor MG132 in Y79 cells. 51 These findings suggest that bortezomib may be incorporated in chemotherapy protocols and used as a chemosensitizer. This approach is under investigation in other malignancies, and a recent phase 1 trial of bortezomib combined with liposomal doxorubicin in patients with advanced hematologic malignancies showed that the combination was safely administered and had enhanced antitumor activity. 52 In summary, we have characterized the molecular signature of bortezomib treatment in two retinoblastoma cell lines and defined apoptotic pathways triggered by this novel anticancer agent. Our study shows that bortezomib suppresses proliferation and cell survival pathways, activates apoptotic and stress pathways, and stimulates transcription of components of the proteasome/ubiquitin and HSP pathways in retinoblastoma cell lines in vitro. Given that the two studied retinoblastoma cell lines have been grown for several years in tissue culture, it may be that they have accumulated additional genetic or epigenetic events and no longer fully recapitulate retinoblastoma pathophysiology. Therefore, additional work in animal models is necessary before clinical trials are initiated in pediatric patients with retinoblastoma. 
